V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 320005516 | 320003841 | 1.78 | 88.6 | Curative (C) | 2017-07-27 | 2017-07-27 | TEMOZOLOMIDE | 01 | N | 320020119 | GEMCITABINE |
| 320005517 | 320003842 | 1.52 | 58.7 | Curative (C) | 2013-06-30 | 2013-09-10 | Bevacizumab+Carbo+Pacliaxel | N | Y | 320020195 | CETUXIMAB + CISPLATIN + FU |
| 320005518 | 320003844 | 1.75 | 57.3 | Curative (C) | 2014-09-17 | 2014-10-26 | Bortezomib +/- Dexamethasone | N | N | 320020198 | BEVACIZUMAB + CARBO + GEMCITABINE |
| 320005519 | 320003846 | 1.58 | null | null | 2017-01-30 | 2017-01-30 | CYCLOPHOSPHAMIDE + VINORELBINE | 2 | N | 320020255 | ICON8B TRIAL |
| 320005520 | 320003847 | 1.81 | 95.7 | Curative (C) | 2014-12-04 | 2014-12-12 | Temozolomide 150mg/m2 | N | N | 320020274 | CETUXIMAB + CISPLATIN + FU |
| 320005522 | 320003849 | 1.62 | 63.65 | Palliative (P) | 2016-10-26 | 2016-12-04 | Bevacizumab + CARBOPLATIN + PACLITAXEL | Y | N | 320020277 | CETUXIMAB + CISPLATIN + FU |
| 320005523 | 320005761 | 1.71 | 105 | Curative (C) | 2016-03-28 | 2016-04-18 | IBRUTINIB | N | N | 320020281 | CARBOPLATIN + RT |
| 320005524 | 320003856 | 1.63 | 96 | Curative (C) | null | 2018-06-19 | POUT TRIAL | 02 | N | 320020283 | BEVACIZUMAB + CARBOPLATIN + PACLITAXEL |
| 320005525 | 320003857 | 1.77 | 93.1 | null | 2018-02-20 | 2018-03-11 | Cyclophosphamide PO +Vinorelbine IV | N | N | 320020319 | CARBOPLATIN + RT |
| 320005526 | 320003857 | 1.72 | 62.4 | Curative (C) | 2017-08-03 | 2017-08-17 | Atezolizumab | Y | Y | 320020319 | POUT TRIAL |
| 320005527 | 320003860 | 1.55 | null | Neo-adjuvant (N) | 2015-11-01 | 2016-02-01 | CARBOPLATIN + RT | N | N | 320020348 | ICON8B TRIAL |
| 320005528 | 320003861 | 0 | 64.1 | Palliative (P) | 2017-07-24 | 2017-07-24 | Docetaxel | 2 | N | 320020359 | TEMOZOLOMIDE |
| 320005529 | 320003862 | 0 | null | Disease modification (D) | 2016-06-03 | 2016-06-23 | Carboplatin + Pemetrexed | N | null | 320020395 | RMS 2005 TRIAL |
| 320005530 | 320003863 | null | 109.6 | Disease modification (D) | 2017-09-30 | 2017-10-14 | CARBOPLATIN + Cetuximab + FLUOROURACIL | N | N | 320020395 | PEMBROLIZUMAB |
| 320005531 | 320003868 | 1.8 | 43.2 | Palliative (P) | 2014-07-19 | 2014-07-19 | Cisplatin + Etoposide (3 day) | 01 | N | 320020416 | CARBOPLATIN + ETOPOSIDE |
| 320005532 | 320003871 | 1.77 | 67.5 | Palliative (P) | 2015-04-04 | 2015-04-17 | Cyclophosphamide PO +Vinorelbine IV | N | N | 320020423 | CETUXIMAB + CISPLATIN + FU |
| 320005533 | 320003871 | null | 57.3 | Palliative (P) | 2015-09-21 | 2015-09-21 | Docetaxel 75mg/m2 (21 day) | N | N | 320020423 | IRINOTECAN + MDG |
| 320005534 | 320003871 | null | 76.7 | Neo-adjuvant (N) | 2017-02-28 | 2017-03-03 | STS Rhabdomyosarcoma RMS 2005 IVA | 1 | N | 320020423 | ICON8B TRIAL |
| 320005535 | 320003873 | 1.7 | 75.15 | Adjuvant (A) | 2016-06-28 | 2016-06-28 | OCTOPUS Trial | 02 | N | 320020504 | CMV |
| 320005536 | 320003874 | 0 | 69.2 | Curative (C) | 2016-08-19 | 2016-08-26 | CARBOPLATIN + FLUOROURACIL | N | N | 320020508 | CARBOPLATIN + RT |
| 320005537 | 320003875 | 1.63 | 42.9 | null | null | 2018-01-27 | GEMCITABINE + TIP | null | null | 320020549 | CETUXIMAB + CISPLATIN + FU |
| 320005538 | 320006677 | 1.8 | 63.5 | Palliative (P) | 2013-09-23 | 2013-09-25 | CARBOPLATIN + Cetuximab + FLUOROURACIL | 02 | N | 320020550 | CARBOPLATIN + CETUXIMAB + FU |
| 320005543 | 320003880 | 1.8 | 62 | Curative (C) | 2015-02-19 | 2015-02-19 | STS Rhabdomyosarcoma RMS 2005 VA | 2 | N | 320020652 | VINCRISTINE |
| 320005544 | 320003883 | 1.78 | null | null | 2017-07-26 | 2017-08-10 | TCF | N | N | 320020692 | CARBOPLATIN + RT |
| 320005545 | 320003884 | 1.63 | null | null | 2013-03-30 | 2013-05-20 | NIVOLUMAB | N | N | 320020709 | BEVACIZUMAB + CARBO + PACLITAXEL |
| 320005546 | 320003889 | 1.67 | 61.1 | Palliative (P) | 2015-11-11 | 2016-03-23 | Bortezomib (weekly) | N | N | 320020718 | BEVACIZUMAB + CARBO + PACLITAXEL |
| 320005547 | 320003892 | null | null | Palliative (P) | null | 2018-11-27 | Carboplatin + Etoposide IV 3 day | null | null | 320020748 | CARBO + FLUOROURACIL |
| 320005548 | 320003895 | 1.59 | 73.1 | Disease modification (D) | 2016-02-24 | 2016-03-02 | BCG Intravesical | N | N | 320020758 | BEVACIZUMAB + CARBOPLATIN + PACLITAXEL |
| 320005549 | 320003895 | 1.6 | 62 | Palliative (P) | 2014-01-06 | 2014-02-03 | STS Rhabdomyosarcoma RMS 2005 IVADo | 02 | N | 320020758 | CISPLATIN + GEMCITABINE |
| 320005550 | 320003895 | 1.67 | 71 | Disease modification (D) | 2015-01-10 | 2015-01-17 | ECarboX | 2 | N | 320020758 | ICON TRIAL |
| 320005551 | 320003896 | 1.73 | 87.5 | Curative (C) | 2014-03-30 | 2014-04-01 | Cisplatin + Docetaxel +Fluorouracil | 02 | N | 320020795 | IMATINIB |
| 320005552 | 320003896 | 1.87 | 94 | Curative (C) | 2017-03-14 | 2017-03-27 | VINCRISTINE | 2 | N | 320020795 | IMATINIB |
| 320005554 | 320005778 | null | 93.1 | Palliative (P) | 2016-12-08 | 2017-09-04 | Carboplatin + Etoposide IV 3 day | N | N | 320020956 | IVA |
| 320005555 | 320003899 | null | null | Palliative (P) | 2013-03-27 | 2013-04-14 | CISPLATIN + DOCETAXEL + FLUOROURACIL | N | Y | 320020976 | RMS 2005 TRIAL |
| 320005556 | 320003902 | 1.7 | null | null | 2014-12-15 | 2014-12-16 | Sunitinib | N | null | 320020984 | MITOXANTRONE |
| 320005557 | 320003902 | 1.76 | 75.6 | Adjuvant (A) | 2015-10-10 | 2015-11-21 | GEMCITABINE | null | null | 320020984 | VEMURAFENIB |
| 320005559 | 320005780 | 1.58 | 57.4 | Neo-adjuvant (N) | 2014-10-29 | 2014-11-12 | Trabectedin | N | N | 320021009 | NIVOLUMAB |
| 320005560 | 320003905 | 1.7 | 78.5 | Palliative (P) | 2014-06-13 | 2014-06-14 | CISPLATIN + DOCETAXEL + FLUOROURACIL | 02 | null | 320021011 | CARBOPLATIN + CETUXIMAB + FLUOROURACIL |
| 320005563 | 320005784 | 1.57 | 71.8 | Palliative (P) | 2014-03-03 | 2014-03-06 | Cisplatin + Liposomal Doxorubicin | N | N | 320021086 | PEMBROLIZUMAB |
| 320005564 | 320005784 | 1.78 | null | Palliative (P) | 2017-10-17 | 2017-11-07 | TEMOZOLOMIDE | Y | N | 320021086 | IMATINIB |
| 320005565 | 320003913 | null | 62.7 | Palliative (P) | 2017-03-23 | 2017-04-18 | POUT TRIAL | N | N | 320021106 | CETUXIMAB + RT |
| 320005566 | 320003913 | 1.56 | 62 | Curative (C) | 2016-08-30 | 2016-09-14 | EW Rel rEECur Irinotecan/Temozolomide | N | N | 320021106 | CARBOPLATIN + METHOTREXATE + VINBLASTINE |
| 320005567 | 320007110 | null | 94.2 | Palliative (P) | 2013-09-03 | 2013-09-03 | Docetaxel 75mg/m2 (21 day) | 02 | N | 320022673 | CAPE + CARBOPLATIN + CETUXIMAB |
| 320005568 | 320007110 | 1.68 | 45 | Neo-adjuvant (N) | 2015-01-31 | 2015-01-31 | CNS Low Grade Glioma Vinblastine | 2 | N | 320022673 | OCTOPUS TRIAL |
| 320005569 | 320007110 | 1.82 | 90 | Palliative (P) | 2016-01-25 | 2016-01-26 | Cetuximab + Radiotherapy Load | 02 | N | 320022673 | CETUXIMAB + CISPLATIN + FLUOROURACIL |
| 320005570 | 320003914 | 1.65 | null | null | 2017-07-11 | 2017-07-17 | POMB/ACE | N | N | 320022701 | CETUXIMAB + RT |
| 320005571 | 320003914 | 1.8 | 79.3 | Palliative (P) | 2014-09-08 | 2014-09-30 | Capecitabine + Oxaliplatin 21day | N | N | 320022701 | ECX |
| 320005572 | 320003914 | 1.67 | 54.1 | Palliative (P) | 2016-12-24 | 2016-12-24 | Capecitabine+Cisplatin+Streptozocin | 2 | Y | 320022701 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 320005573 | 320003915 | 1.67 | 69.8 | null | 2016-03-05 | 2016-03-05 | Niraparib | 2 | N | 320022738 | BEVACIZUMAB + CARBO + PACLITAXEL |
| 320005574 | 320003916 | 1.73 | 70.3 | Palliative (P) | 2016-04-03 | 2016-04-03 | TEMOZOLOMIDE | 2 | N | 320022743 | TEMOZOLOMIDE |